High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity

Figure 7 Therapeutic efficacy of high-frequency irreversible electroporation combined with BMS-1 and R848 in the hepatoma 22 bilateral tumor-bearing mice. A: Schematic of the hepatoma 22 bilateral tumor-bearing mice and treatment regimen; B: Dynamic changes in left tumor volume of hepatoma 22 bilateral tumor-bearing mice post-treatment (n = 8); C: Comparison of left tumor volumes on day 21 post-treatment (n = 8); D: Quantitative analysis of TUNEL-positive cell proportion in left tumors 1 week post-treatment (n = 8); E: Representative TUNEL staining images of left-sided tumors from each group 1 week post-treatment. ^dP < 0.0001. i.p.: Intraperitoneal; i.t.: Intratumoral; H-FIRE: High-frequency irreversible electroporation; H22: Hepatoma 22.